Pfizer's Torisel misses endpoint in second kidney cancer trial this year
This article was originally published in Scrip
Executive Summary
Pfizer posted its second set of topline results this year for a failed clinical trial seeking to expand the approved label for the oncology drug Torisel (temsirolimus) in renal cell carcinoma (RCC), this time in combination with Roche/Genentech's Avastin (bevacizumab).